ADQUEY Drug Patent Profile

Which patents cover Adquey, and what generic alternatives are available?

Adquey is a drug marketed by Acrotech Biopharma and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-four patent family members in twenty-six countries.

The generic ingredient in ADQUEY is difamilast. One supplier is listed for this compound. Additional details are available on the difamilast profile page.

DrugPatentWatch^® Generic Entry Outlook for Adquey

Adquey will be eligible for patent challenges on February 12, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 31, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ADQUEY

International Patents:	54
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ADQUEY

ADQUEY is protected by two US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes			Y	Y
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes			Y	Y
Acrotech Biopharma	ADQUEY	difamilast	OINTMENT;TOPICAL	219474-001	Feb 12, 2026		RX	Yes	Yes

International Patents for ADQUEY

When does loss-of-exclusivity occur for ADQUEY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Hong Kong

Japan

Malaysia

New Zealand

Philippines

Saudi Arabia

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ADQUEY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016382036
Canada	3009734
China	108473448
Denmark	3397619
European Patent Office	3397619
Spain	2811849

Investment Scenario and Fundamentals Analysis for ADQUEY (Cemiplimab-rwlc)

Last updated: April 5, 2026

What is ADQUEY and its Market Position?

ADQUEY (cemiplimab-rwlc) is a PD-1 inhibitor developed by Regeneron Pharmaceuticals. It is approved for treating certain cancers, including cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), basal cell carcinoma (BCC), and other indications. The drug’s market positioning relies on its differentiation in immune checkpoint inhibition, competing primarily with Merck’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).

What Are the Key Drivers in the ADQUEY Investment Scenario?

Regulatory Status and Approvals

• FDA Approval: Approved in 2021 for CSCC, expanding indications involve NSCLC, BCC, and other tumors, with accelerated pathways used for certain labels.
• Europe and Other Markets: Regulatory filings underway; approval pending or granted in select markets.
• Expansion Opportunities: Indications in head and neck, gastric, and other cancers provide potential revenue streams.

Market Size and Growth

Tumor Type	Estimated Global Market (2023)	CAGR (2023-2028)	Key Competitors	Regulatory Status
Cutaneous Squamous Cell Carcinoma	$1.2 billion	8%	Cemiplimab, Pembrolizumab	Approved in US, EU
Non-Small Cell Lung Cancer	$18 billion	9%	Keytruda, Opdivo	Approved in US and EU
Basal Cell Carcinoma	$1.8 billion	7%	Cemiplimab, Vismodegib	Approved in US, EU

Growth in these segments derives from increasing cancer incidences, enhanced indication approvals, and improved survival rates associated with immune checkpoint inhibitors.

Competitive Dynamics

• Differentiators: Cemiplimab offers similar efficacy to competitors with a potentially improved safety profile or dosing schedule.
• Patent Exclusivity: Patent protection extends through 2028-2030, with some as late as 2032 domestically.
• Market Penetration: Limited initial market share due to ongoing competition; substantial growth projected with indication expansion.

Financial Considerations

• Revenue Projections: Led by sales in CSCC, with estimates reaching $600 million in 2023 and an annual growth rate of 20% through 2028.
• R&D and Marketing Expenses: Substantial investments necessary for indication expansion and label updates.
• Profitability Outlook: Insufficient data to assert profitability, but scale and indication breadth influence positive margins.

Pipeline and Development

Program	Stage	Potential Indications	Expected Launch Year
Advanced NSCLC trials	Phase 3	First-line therapy, combo regimens	2024-2026
Head and neck cancers	Phase 2/3	Expanding use cases	2025-2027
Adjuvant and neoadjuvant settings	Preclinical-Phase 2	Ongoing research	2026-2028

The pipeline’s success depends on trial outcomes, regulatory approvals, and market uptake.

What Risks Are Associated with Investing in ADQUEY?

Clinical and Regulatory Risks

Variability in trial outcomes poses uncertainties. While current data is promising, failures or delays in pivotal studies could impact revenue projections.

Competitive Risks

Keytruda and Opdivo have broader oncology portfolios and entrenched market presence, making incremental growth challenging for cemiplimab.

Pricing and Reimbursement

Shifts in healthcare policies or payer negotiations may constrain pricing, affecting revenue and margins.

Patent and Legal Risks

Potential patent litigations and late-stage generic challenges after patent expiry could weaken market positioning.

Market Adoption

Physician and patient preferences, along with safety profiles, influence adoption rates, especially for new indications.

Summary of Investment Fundamentals

Aspect	Data	Implication
Revenue (2023)	Estimated $600 million for core indications	Significant growth expected; driven by expanded indications
Market Penetration	Limited but growing; competition remains stiff	Market share increases with clinical success and strategic commercialization
Pipeline Strength	Multiple Phase 2/3 trials, pipeline expansion	Potential for future revenue streams, but dependent on successful trial outcomes
Patent Duration	Extends into early 2030s	Provides period of market exclusivity, albeit with looming patent cliff
Regulatory Pathways	Approvals in US, EU, other regions	Facilitated by accelerated pathways; international expansion critical

Key Takeaways

• ADQUEY operates within a competitive sector with high growth potential caused by expanding indications in oncology.
• Financial success hinges on successful trial outcomes, regulatory approvals, and market access strategies.
• Competition from established checkpoint inhibitors complicates market penetration.
• Patent exclusivity and pipeline development are critical for ongoing revenue generation.
• Risks from clinical failures, pricing pressures, and legal challenges persist.

FAQs

1. What are the primary indications for ADQUEY?
   Current approved indications include cutaneous squamous cell carcinoma, with expanded uses in NSCLC and basal cell carcinoma.

2. What is the competitive landscape for cemiplimab?
   It competes mainly with pembrolizumab and nivolumab, which have broader approved oncology portfolios and longer market presence.

3. What are the key risks impacting ADQUEY investments?
   Clinical trial failures, delayed regulatory approvals, market competition, and patent expirations.

4. What is the potential revenue growth for cemiplimab?
   Projected to grow around 20% annually through 2028, driven by indications expansion and global market penetration.

5. When do key patent protections expire?
   Patent rights extend into the early 2030s, after which generic or biosimilar competition is possible.

References

[1] Regeneron Pharmaceuticals. (2023). ADQUEY (cemiplimab-rwlc) Prescribing Information.
[2] GlobalData. (2023). Oncology Market Analysis 2023.
[3] IQVIA. (2023). Oncology Drug Market Trends.
[4] FDA. (2021). Approval Letter for Cemiplimab for Cutaneous Squamous Cell Carcinoma.
[5] Evaluate Pharma. (2023). Oncology Market Forecast.